A Rare Case and Atypical Metastatic Regions, Pulmonary Giant Cell Carcinoma.

Sixty two years old man referred to our clinic due to suspicion of thymic mass. The hypermetabolic nodular lesion in the right lung upper lobe was seen in F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in addition to the mass in the anterior mediastinum which was found to without malignancy. The patient underwent wedge resection and final diagnosis was pulmonary giant cell carcinoma.

Somatostatin receptor-positive breast lesions on Ga-DOTATATE PET/CT.

Objective: This study sets out to evaluate patients with increased uptake in breast lesions on Ga-DOTATATE PET/CT (DOTA PET) and determine the clinical significance of somatostatin receptor (SSTR) positive breast lesions.

Methods: We retrospectively evaluated all patients with increased SSTR uptake in breast lesions on DOTA PET. Patients with physiological (e.

Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?

Background: Peptide receptor radionuclide therapy and selective internal radiation therapy are effective radionuclide therapy modalities for unresectable metastatic neuroendocrine tumor patients that cannot be controlled with somatostatin analogs. The present study is intended to evaluate the therapeutic efficacy and toxicity of the combined therapy of selective internal radiation therapy and peptide receptor radionuclide therapy and stand-alone selective internal radiation therapy in patients with neuroendocrine tumor, a liver-dominant disease.

Methods: This cohort consists of 27 patients with metastatic neuroendocrine tumor and liver-dominant disease.

Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D'Amico risk classification.

Purpose: We aimed to investigate the diagnostic power of 68Ga-PSMA PET/CT in the detection of metastatic spread of newly diagnosed PCa, and evaluate the relationship with modified D'Amico risk classification.

Methods: We evaluated newly diagnosed PCa patients who underwent 68Ga-PSMA PET/CT prior to therapy. All images were interpreted retrospectively and areas of abnormally increased tracer uptake were documented according to PSMA-RADS version 1.

Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer?

Objection: We aimed to evaluate the role of bone scintigraphy (BS) which has long been the imaging modality of choice in prostate cancer (PCa) and performed a head-to-head comparison between BS, BS + SPECT/CT and 68 Ga-PSMA-PET/CT, for the detection of bone metastasis of PCa.

Methods: We evaluated 138 PCa patients who underwent BS and 68 Ga-PSMA PET/CT and SPECT/CT of 102 of 138 patients. Images were interpreted retrospectively and areas of abnormally increased tracer uptake related to PCa were documented as benign, metastatic or equivocal.

Clinical Impact of Lower-Limb Imaging in Ga-PSMA PET/CT for Patients with Prostate Cancer.

Our purpose was to determine whether there is a clinical benefit to add lower-limb imaging in Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT scans for patients with prostate cancer. In total, 701 patients with prostate cancer who underwent Ga-PSMA PET/CT were evaluated retrospectively. All patients underwent additional lower-limb imaging.